Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.

Benjamin R. Bellenie,Kwai-Ming J. Cheung,Ana Varela,Olivier A. Pierrat,Gavin W. Collie,Gary Box,Michael D. Bright,Sharon Gowan,Angela Hayes,Matthew J Rodrigues,Kartika N. Shetty,Michael Carter,Owen A. Davis,Alan T. Henley,Paolo Innocenti,Louise Johnson,Manjuan Liu,Selby de Klerk,Yann-Vaï Le Bihan,Matthew G. Lloyd,P. Craig McAndrew,Erald Shehu,Rachel Talbot,Hannah L. Woodward,Rosemary Burke,Vladimir Kirkin,Rob L. M. van Montfort,Florence I. Raynaud,Olivia W. Rossanese,Swen Hoelder

Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.

2020

Deregulation of the transcriptional repressor BCL6 enables tumorigenesis of germinal center B-cells, and hence BCL6 has been proposed as a therapeutic target for the treatment of diffuse large B-ce...

Keywords:

Germinal center
BCL6
Transcriptional Repressor
Cell biology
In vivo
Carcinogenesis
Chemistry
Biochemistry

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations